LymphedemaV1, Main, Exploration, bibRecord, 009B29

Placebo-controlled community trial of four cycles of single-dose diethylcarbamazine or ivermectin against Wuchereria bancrofti infection and transmission in India

Identifieur interne : 009B29 ( Main/Exploration ); précédent : 009B28; suivant : 009B30

Placebo-controlled community trial of four cycles of single-dose diethylcarbamazine or ivermectin against Wuchereria bancrofti infection and transmission in India

Auteurs : P. K. Das [Inde] ; K. D. Ramaiah [Inde] ; P. Vanamail [Inde] ; S. P. Pani [Inde] ; J. Yuvaraj [Inde] ; K. Balarajan [Inde] ; D. A. P. Bundy [Royaume-Uni]

Source :

Transactions of The Royal Society of Tropical Medicine and Hygiene [ 0035-9203 ] ; 2001-06.

RBID : ISTEX:CB10AEF33B0BDB57C80A89AFE8099528589C393A

Descripteurs français

Wicri :
- geographic : Inde.

English descriptors

KwdEn :
- India, community treatment, diethylcarbamazine, disease control, filariasis, ivermectin, prevalence, transmission.

Abstract

A double-blind placebo-controlled trial was carried out in 1994–1998 to compare the effects of 4 cycles of single-dose diethylcarbamazine (DEC) or ivermectin on prevalence and geometric mean intensity (GMI) of microfilaraemia in the human population, infection rates in the vector population, and transmission intensity of Culex-transmitted Wuchereria bancrofti in rural areas in Tamil Nadu state, south India. Fifteen villages (population 26 800) were included in the study: 5 villages each were randomly assigned to community-wide treatment with DEC or ivermectin or placebo. People over 14 kg bodyweight received DEC 6 mg/kg, ivermectin 400 gmg/kg or a placebo, all identically packaged. After 2 cycles of treatment at a 6-month interval, the code was broken and the study continued as an open trial, with third and fourth cycles of treatment at a 12-month interval; 54–77% of eligible people (20 872) received treatment during the 4 cycles. Microfilaraemia prevalence and GMI fell by 48% and 65% with DEC and 60% and 80% with ivermectin respectively after 4 cycles of treatment. There was no change in the incidence of acute adenolymphangitis. Infection in resting mosquitoes fell significantly in all arms: 82%, 78% and 42% in the ivermectin, DEC and placebo arm, respectively. Landing mosquitoes also showed the same trend. The decline in infectivity was significant for resting (P < 0·05) and landing mosquitoes (P < 0·05) with ivermectin and DEC (P < 0·05), and for neither in the placebo group (P > 0·05). Transmission intensity was reduced by 68% with ivermectin and 63% with DEC. Transmission was apparently interrupted in 1 village with ivermectin, but infected resting mosquitoes were consistently found in this village. Single-dose community-level treatment with DEC or ivermectin is effective in reducing W. bancrofti infection in humans and mosquitoes, and may result in total interruption of transmission after several years of control. There is an immediate need to define the role of vector, parasite and community factors that influence the elimination of lymphatic filariasis, particularly the duration of treatment vis-à-vis efficacy of drugs, treatment compliance and efficiency of vectors.

Url:

DOI: 10.1016/S0035-9203(01)90260-3

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Placebo-controlled community trial of four cycles of single-dose diethylcarbamazine or ivermectin against Wuchereria bancrofti infection and transmission in India</title>
<author><name sortKey="Das, P K" sort="Das, P K" uniqKey="Das P" first="P. K." last="Das">P. K. Das</name>
</author>
<author><name sortKey="Ramaiah, K D" sort="Ramaiah, K D" uniqKey="Ramaiah K" first="K. D." last="Ramaiah">K. D. Ramaiah</name>
</author>
<author><name sortKey="Vanamail, P" sort="Vanamail, P" uniqKey="Vanamail P" first="P." last="Vanamail">P. Vanamail</name>
</author>
<author><name sortKey="Pani, S P" sort="Pani, S P" uniqKey="Pani S" first="S. P." last="Pani">S. P. Pani</name>
</author>
<author><name sortKey="Yuvaraj, J" sort="Yuvaraj, J" uniqKey="Yuvaraj J" first="J." last="Yuvaraj">J. Yuvaraj</name>
</author>
<author><name sortKey="Balarajan, K" sort="Balarajan, K" uniqKey="Balarajan K" first="K." last="Balarajan">K. Balarajan</name>
</author>
<author><name sortKey="Bundy, D A P" sort="Bundy, D A P" uniqKey="Bundy D" first="D. A. P." last="Bundy">D. A. P. Bundy</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:CB10AEF33B0BDB57C80A89AFE8099528589C393A</idno>
<date when="2001" year="2001">2001</date>
<idno type="doi">10.1016/S0035-9203(01)90260-3</idno>
<idno type="url">https://api.istex.fr/document/CB10AEF33B0BDB57C80A89AFE8099528589C393A/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">005F20</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">005F20</idno>
<idno type="wicri:Area/Istex/Curation">005F20</idno>
<idno type="wicri:Area/Istex/Checkpoint">002823</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">002823</idno>
<idno type="wicri:doubleKey">0035-9203:2001:Das P:placebo:controlled:community</idno>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:F405E0A14D062E4D5A6508EADB425E03FEFE427C</idno>
<idno type="url">https://api.istex.fr/document/F405E0A14D062E4D5A6508EADB425E03FEFE427C/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">007242</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">007242</idno>
<idno type="wicri:Area/Istex/Curation">007242</idno>
<idno type="wicri:Area/Istex/Checkpoint">002822</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">002822</idno>
<idno type="wicri:doubleKey">0035-9203:2001:Das P:placebo:controlled:community</idno>
<idno type="wicri:Area/Main/Merge">009F78</idno>
<idno type="wicri:Area/Main/Curation">009B29</idno>
<idno type="wicri:Area/Main/Exploration">009B29</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a">Placebo-controlled community trial of four cycles of single-dose diethylcarbamazine or ivermectin against Wuchereria bancrofti infection and transmission in India</title>
<author><name sortKey="Das, P K" sort="Das, P K" uniqKey="Das P" first="P. K." last="Das">P. K. Das</name>
<affiliation wicri:level="1"><country xml:lang="fr">Inde</country>
<wicri:regionArea>Vector Control Research Centre, Medical Complex, Indira Nagar, Pondicherry 605006</wicri:regionArea>
<wicri:noRegion>Pondicherry 605006</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">Inde</country>
</affiliation>
</author>
<author><name sortKey="Ramaiah, K D" sort="Ramaiah, K D" uniqKey="Ramaiah K" first="K. D." last="Ramaiah">K. D. Ramaiah</name>
<affiliation wicri:level="1"><country xml:lang="fr">Inde</country>
<wicri:regionArea>Vector Control Research Centre, Medical Complex, Indira Nagar, Pondicherry 605006</wicri:regionArea>
<wicri:noRegion>Pondicherry 605006</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Vanamail, P" sort="Vanamail, P" uniqKey="Vanamail P" first="P." last="Vanamail">P. Vanamail</name>
<affiliation wicri:level="1"><country xml:lang="fr">Inde</country>
<wicri:regionArea>Vector Control Research Centre, Medical Complex, Indira Nagar, Pondicherry 605006</wicri:regionArea>
<wicri:noRegion>Pondicherry 605006</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pani, S P" sort="Pani, S P" uniqKey="Pani S" first="S. P." last="Pani">S. P. Pani</name>
<affiliation wicri:level="1"><country xml:lang="fr">Inde</country>
<wicri:regionArea>Vector Control Research Centre, Medical Complex, Indira Nagar, Pondicherry 605006</wicri:regionArea>
<wicri:noRegion>Pondicherry 605006</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Yuvaraj, J" sort="Yuvaraj, J" uniqKey="Yuvaraj J" first="J." last="Yuvaraj">J. Yuvaraj</name>
<affiliation wicri:level="1"><country xml:lang="fr">Inde</country>
<wicri:regionArea>Vector Control Research Centre, Medical Complex, Indira Nagar, Pondicherry 605006</wicri:regionArea>
<wicri:noRegion>Pondicherry 605006</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Balarajan, K" sort="Balarajan, K" uniqKey="Balarajan K" first="K." last="Balarajan">K. Balarajan</name>
<affiliation wicri:level="1"><country xml:lang="fr">Inde</country>
<wicri:regionArea>Vector Control Research Centre, Medical Complex, Indira Nagar, Pondicherry 605006</wicri:regionArea>
<wicri:noRegion>Pondicherry 605006</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bundy, D A P" sort="Bundy, D A P" uniqKey="Bundy D" first="D. A. P." last="Bundy">D. A. P. Bundy</name>
<affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Wellcome Trust Centre for the Epidemiology of Infectious Disease, University of Oxford, South Parks Road, Oxford OX1 3FY</wicri:regionArea>
<orgName type="university">Université d'Oxford</orgName>
<placeName><settlement type="city">Oxford</settlement>
<region type="nation">Angleterre</region>
<region type="région" nuts="1">Oxfordshire</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Transactions of The Royal Society of Tropical Medicine and Hygiene</title>
<title level="j" type="abbrev">Trans R Soc Trop Med Hyg</title>
<idno type="ISSN">0035-9203</idno>
<idno type="eISSN">1878-3503</idno>
<imprint><publisher>Royal Society of Tropical Medicine and Hygiene</publisher>
<date type="published" when="2001-06">2001-06</date>
<biblScope unit="volume">95</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="336">336</biblScope>
<biblScope unit="page" to="341">341</biblScope>
</imprint>
<idno type="ISSN">0035-9203</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0035-9203</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>India</term>
<term>community treatment</term>
<term>diethylcarbamazine</term>
<term>disease control</term>
<term>filariasis</term>
<term>ivermectin</term>
<term>prevalence</term>
<term>transmission</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Inde</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract">A double-blind placebo-controlled trial was carried out in 1994–1998 to compare the effects of 4 cycles of single-dose diethylcarbamazine (DEC) or ivermectin on prevalence and geometric mean intensity (GMI) of microfilaraemia in the human population, infection rates in the vector population, and transmission intensity of Culex-transmitted Wuchereria bancrofti in rural areas in Tamil Nadu state, south India. Fifteen villages (population 26 800) were included in the study: 5 villages each were randomly assigned to community-wide treatment with DEC or ivermectin or placebo. People over 14 kg bodyweight received DEC 6 mg/kg, ivermectin 400 gmg/kg or a placebo, all identically packaged. After 2 cycles of treatment at a 6-month interval, the code was broken and the study continued as an open trial, with third and fourth cycles of treatment at a 12-month interval; 54–77% of eligible people (20 872) received treatment during the 4 cycles. Microfilaraemia prevalence and GMI fell by 48% and 65% with DEC and 60% and 80% with ivermectin respectively after 4 cycles of treatment. There was no change in the incidence of acute adenolymphangitis. Infection in resting mosquitoes fell significantly in all arms: 82%, 78% and 42% in the ivermectin, DEC and placebo arm, respectively. Landing mosquitoes also showed the same trend. The decline in infectivity was significant for resting (P < 0·05) and landing mosquitoes (P < 0·05) with ivermectin and DEC (P < 0·05), and for neither in the placebo group (P > 0·05). Transmission intensity was reduced by 68% with ivermectin and 63% with DEC. Transmission was apparently interrupted in 1 village with ivermectin, but infected resting mosquitoes were consistently found in this village. Single-dose community-level treatment with DEC or ivermectin is effective in reducing W. bancrofti infection in humans and mosquitoes, and may result in total interruption of transmission after several years of control. There is an immediate need to define the role of vector, parasite and community factors that influence the elimination of lymphatic filariasis, particularly the duration of treatment vis-à-vis efficacy of drugs, treatment compliance and efficiency of vectors.</div>
</front>
</TEI>
<affiliations><list><country><li>Inde</li>
<li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Oxfordshire</li>
</region>
<settlement><li>Oxford</li>
</settlement>
<orgName><li>Université d'Oxford</li>
</orgName>
</list>
<tree><country name="Inde"><noRegion><name sortKey="Das, P K" sort="Das, P K" uniqKey="Das P" first="P. K." last="Das">P. K. Das</name>
</noRegion>
<name sortKey="Balarajan, K" sort="Balarajan, K" uniqKey="Balarajan K" first="K." last="Balarajan">K. Balarajan</name>
<name sortKey="Das, P K" sort="Das, P K" uniqKey="Das P" first="P. K." last="Das">P. K. Das</name>
<name sortKey="Pani, S P" sort="Pani, S P" uniqKey="Pani S" first="S. P." last="Pani">S. P. Pani</name>
<name sortKey="Ramaiah, K D" sort="Ramaiah, K D" uniqKey="Ramaiah K" first="K. D." last="Ramaiah">K. D. Ramaiah</name>
<name sortKey="Vanamail, P" sort="Vanamail, P" uniqKey="Vanamail P" first="P." last="Vanamail">P. Vanamail</name>
<name sortKey="Yuvaraj, J" sort="Yuvaraj, J" uniqKey="Yuvaraj J" first="J." last="Yuvaraj">J. Yuvaraj</name>
</country>
<country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Bundy, D A P" sort="Bundy, D A P" uniqKey="Bundy D" first="D. A. P." last="Bundy">D. A. P. Bundy</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 009B29 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 009B29 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:CB10AEF33B0BDB57C80A89AFE8099528589C393A
   |texte=   Placebo-controlled community trial of four cycles of single-dose diethylcarbamazine or ivermectin against Wuchereria bancrofti infection and transmission in India
}}

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

Serveur d'exploration sur le lymphœdème

Placebo-controlled community trial of four cycles of single-dose diethylcarbamazine or ivermectin against Wuchereria bancrofti infection and transmission in India

Placebo-controlled community trial of four cycles of single-dose diethylcarbamazine or ivermectin against Wuchereria bancrofti infection and transmission in India

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.